HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Science
; 352(6288): 997-1001, 2016 May 20.
Article
em En
| MEDLINE
| ID: mdl-27199429
3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Viremia
/
Anticorpos Anti-HIV
/
Infecções por HIV
/
HIV-1
/
Imunização Passiva
/
Anticorpos Neutralizantes
/
Anticorpos Monoclonais
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article